Media Mosiac Gov Solutions Book a Strategy Call
Gov.MediaMosiac β€Ί GovCon News
πŸ› GovCon Intel Opportunities Presolicitations Contract Awards Award Notices Grants Events Regulatory Search πŸ“ Insights
← Back to Regulatory Updates

Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments

Proposed Rule πŸ’¬ Comment by Sep 11 (44d left)
Health and Human Services Department, Food and Drug Administration
Proposed Rule
July 13, 2026
2026-14073
21 CFR 207
September 11, 2026 (44 days left)

πŸ“„ Summary

The Food and Drug Administration (FDA, the Agency, or we) is proposing to amend the drug establishment registration and drug listing requirements with respect to establishments engaged in distributed manufacturing and foreign drug establishments. This action, if finalized, will provide a pathway for a distributed manufacturing establishment that manufactures drugs at multiple different physical locations to register as a single drug manufacturing establishment and align drug establishment registration and drug listing regulations applicable to foreign drug establishments with statutory changes made by the Preparing for and Responding to Existing Viruses, Emerging New Threats, and Pandemics Act (PREVENT Pandemics Act).
🎯 Get GovCon Intel Free β†’